SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 18th, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 16, 2015, between Accurexa Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 18th, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 16, 2015, between Accurexa Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANTAccurexa Inc. • June 18th, 2015 • Electromedical & electrotherapeutic apparatus
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the four (4) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Accurexa Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EMPLOYMENT AGREEMENTEmployment Agreement • January 19th, 2017 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This employment agreement (this "Agreement") dated as of January 19, 2017 (the "Effective Date"), is made by and between Accurexa Inc., a Delaware corporation (the "Company") and Bryan Lee (the “Executive”) (collectively, the “Parties”).
Investigator Initiated Research Study AgreementInvestigator Initiated Research Study Agreement • April 23rd, 2013 • Cyto Wave Technologies Inc. • Electromedical & electrotherapeutic apparatus • Arkansas
This Investigator Initiated Study Agreement (the “Agreement”) sets forth the understanding between Cyto Wave Technolocies, Inc., a medical technology company located in 201 Spear Street, Suite 1100, San Francisco, CA 94105 (“CytoWave”) and The Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences (“Sponsor-Institute”) on behalf of its employee, Laura Hutchins, M.D. and Vladimir Zharov, Ph.D. (“Sponsor-Investigator”) concerning the Investigator Initiated Research Plan entitled: “Optimization Of An Experimental Prototype For Photoacoustic Detection Of Circulating Melanoma Cells And Clinical Trials In Humans” (“Research Plan”) and the Sponsor-Investigator’s clinical study protocol (the “Study”) entitled “In Vivo Real-Time Detection of Circulating Melanoma Cells”, Protocol #133965 (the “Protocol”), collectively referred herein as the “Research Project”.
Agreement for the Rendering of ServicesRendering of Services • November 2nd, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus
THIS AGREEMENT for the rendering of services (the “Agreement”) is entered into as of November 1, 2015 ("Effective Date") by and between Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) and Accurexa, Inc. (“Company”).
SUBLICENSE AGREEMENTSublicense Agreement • February 7th, 2017 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Marshall Islands
This Sublicense Agreement (this “Agreement”) is dated as of January 31, 2017 (“Effective Date”), by and among ACCUREXA INC., a company incorporated in the Republic of the Marshall Islands (“Accurexa”) and CNMRGS Inc., a private company incorporated in the British Virgin Islands (“CNM”). Each of Accurexa and CNM is referred to herein as a “Party” and collectively, as the “Parties.”
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • July 22nd, 2016 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Delaware
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 27th, 2013 • Cyto Wave Technologies Inc. • Arkansas
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) by and between the Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences, a public institution of higher education having principal offices at 2404 North University Avenue, Little Rock, Arkansas 72207 United States of America ("UNIVERSITY"), and Cyto Wave Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware, with principal offices located at 201 Spear Street, Suite 1100, San Francisco, CA 94105, United States of America ("LICENSEE"), is effective as of December 15, 2012 (“Effective Date”).
LICENSE TERMINATION AGREEMENTLicense Termination Agreement • August 20th, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Arkansas
THIS LICENSE TERMINATION AGREEMENT (“Agreement”) is executed as of August 18, 2015 (“Termination Date”), by and between the Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences, a public institution of higher education having principal offices at 4301 West Markham Street #831, Little Rock, Arkansas 72205-7199 USA ("University"), and Accurexa Inc., a Delaware Corporation formerly known as Cyto Wave Technologies, Inc. and having offices at 113 Barksdale, Newark, DE 19711 USA (“Accurexa”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • July 25th, 2017 • Medisun Precision Medicine Ltd. • Electromedical & electrotherapeutic apparatus • Hong Kong
SUN MEDICAL OPERATION COMPANY LIMITED, a limited liability company incorporated in the British Virgin Islands, whose registered office is situated at Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands (“Vendor”); and
LICENSE AGREEMENTLicense Agreement • June 9th, 2017 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Marshall Islands
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • July 10th, 2017 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus
THIS PATENT ASSIGNMENT AGREEMENT (the “Agreement”) is signed by the following Parties and is effective as of 7th July, 2017 (the “Effective Date”):
SHARE PURCHASE AGREEMENTShare Purchase Agreement • February 27th, 2013 • Cyto Wave Technologies Inc. • Delaware
This Share Purchase Agreement (this “Agreement”) is dated as of _________, among Cyto Wave Technologies Inc., a Delaware corporation (the “Company”), and ________ (the “Investor”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 12th, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Delaware
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) by and between Accelerating Combination Therapies, LLC, a limited liability company under of the state of Maryland, having its principal place of business at 1550 Orleans St., Baltimore, Maryland 21287 ("ACL"), and Accurexa, Inc., a corporation organized and existing under the laws of the State of Delaware, with principal offices located at 113 Barksdale, Newark, DE 19711, United States of America ("LICENSEE"), is effective as of August 11, 2015 (“Effective Date”).
ACCUREXA INC. CONSULTING AGREEMENTConsulting Agreement • January 13th, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • California
This Consulting Agreement (this “Agreement”) is dated and effective as of January 12, 2015 (the “Effective Date”), between ACCUREXA INC., a Delaware company (the “Company”) and LIM DEVELOPMENT GROUP, a California corporation (“Consultant”).
THIS SETTLEMENT AGREEMENT (“Agreement”) dated 9th day of August, 2017 is made BETWEEN:Settlement Agreement • August 11th, 2017 • Medisun Precision Medicine Ltd. • Electromedical & electrotherapeutic apparatus
CONSULTING AGREEMENTConsulting Agreement • March 25th, 2015 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Consulting Agreement (the “Agreement”), effective as of February 18, 2015 (“Effective Date”) and is entered into by and between, Accurexa, Inc., Inc., a Delaware corporation (herein referred to as the “Company”) and Capital Group Communications, Inc., a California corporation with principal address at 575 Bridgeway, Sausalito CA 94965 (herein referred to as the “Consultant”). As used in this Agreement, the term, “Parties,” shall refer to the Company and Consultant jointly.
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and ACCUREXA, INC. forExclusive License Agreement • September 17th, 2014 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • California
This exclusive license agreement ("Agreement") is made effective September 16, 2014 ("Effective Date"), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 ("The Regents") and acting through its Office of Innovation, Technology, and Alliances, University of California San Francisco (“UCSF”), 3333 California Street, Suite S-11, San Francisco, CA 94143 and Accurexa, Inc., a Delaware corporation, having a principal place of business at 201 Spear Street, Suite 1100, San Francisco 94105 ("Licensee").
LICENSE AGREEMENTLicense Agreement • May 17th, 2017 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Marshall Islands
This License Agreement (this “Agreement”) is dated as of 18th April, 2017 (“Agreement Date”), by and between (a) ACCUREXA INC. (“Accurexa”), a company incorporated in the Republic of the Marshall Islands (the “Marshall Islands”), whose registered office and principal place of business is situated at MH 96960 Ajeltake Road, Majuro, Marshall Islands; and (b) Medisun Holdings Limited (“Medisun”), a company incorporated in the Hong Kong Special Administrative Region (“Hong Kong”) of the People’s Republic of China (“PRC”, together with Hong Kong, the Macau Special Administrative Region and Taiwan, collectively, the “Greater China”), whose registered office and principal place of business is situated at 25/F., Octa Tower, 8 Lam Chak Street, Kowloon Bay, Hong Kong.
